Cargando…

CAR T-Cell Therapy in Hematological Malignancies

Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haslauer, Theresa, Greil, Richard, Zaborsky, Nadja, Geisberger, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396650/ https://www.ncbi.nlm.nih.gov/pubmed/34445701 http://dx.doi.org/10.3390/ijms22168996

Ejemplares similares

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021)

Rac GTPases in Hematological Malignancies
por: Durand-Onaylı, Valerie, et al.
Publicado: (2018)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia
por: Gassner, Franz J., et al.
Publicado: (2020)

Detecting Bacterial–Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia
por: Akimova, Ekaterina, et al.
Publicado: (2022)

Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity
por: Geisberger, Roland, et al.
Publicado: (2012)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Validation of genetic variants from NGS data using deep convolutional neural networks
por: Vaisband, Marc, et al.
Publicado: (2023)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report
por: Steiner, Markus, et al.
Publicado: (2021)

AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells
por: Huemer, Michael, et al.
Publicado: (2014)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia
por: Rebhandl, Stefan, et al.
Publicado: (2014)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
por: Liu, Qianzhen, et al.
Publicado: (2022)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining
por: Akimova, Ekaterina, et al.
Publicado: (2021)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
por: Tan, Jing Yuan, et al.
Publicado: (2022)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL
por: Schubert, Maria, et al.
Publicado: (2021)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia
por: Parigger, Thomas, et al.
Publicado: (2021)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
por: Cao, Xinping, et al.
Publicado: (2023)

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development
por: Zaborsky, Nadja, et al.
Publicado: (2018)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Mouse models to decipher anti-tumor immunity
por: Parigger, Thomas, et al.
Publicado: (2019)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d5ioivebf3q6qav4u9vj4i4rgs